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Abstract
Background: Many evidences report that alternative splicing, the mechanism which produces mRNAs and proteins
with different structures and functions from the same gene, is altered in cancer cells. Thus, the identification and
characterization of cancer-specific splice variants may give large impulse to the discovery of novel diagnostic and
prognostic tumour biomarkers, as well as of new targets for more selective and effective therapies.
Results: We present here a genome-wide analysis of the alternative splicing pattern of human genes through a
computational analysis of normal and cancer-specific ESTs from seventeen anatomical groups, using data available
in AspicDB, a database resource for the analysis of alternative splicing in human. By using a statistical
methodology, normal and cancer-specific genes, splice sites and cassette exons were predicted in silico. The
condition association of some of the novel normal/tumoral cassette exons was experimentally verified by RT-qPCR
assays in the same anatomical system where they were predicted. Remarkably, the presence in vivo of the
predicted alternative transcripts, specific for the nervous system, was confirmed in patients affected by
glioblastoma.
Conclusion: This study presents a novel computational methodology for the identification of tumor-associated
transcript variants to be used as cancer molecular biomarkers, provides its experimental validation, and reports
specific biomarkers for glioblastoma.
Background
Alternative splicing (AS) is a pivotal regulation mechan-
ism allowing the expansion of the genome expression
potential through the generation of multiple transcripts
from a single gene. Indeed, over 90% of multi-exon
genes undergo AS [1] generating on average a tenfold
expansion of the transcriptome complexity [2]. Alterna-
tively spliced exons have splice sites that can be specifi-
cally recognized depending on tissue specificity,
developmental stage, external stimuli, cellular stress, or
even pathological conditions [3]. So the presence or the
expression level of specific splice variants can be indica-
tive of a pathological or physiological condition or even
be the cause of a disease. Recent studies demonstrated
that alternative isoforms can be linked to many patholo-
gies among which cancer, and play important roles in
their etiopathogenesis [4]. Indeed, changes in the spli-
cing pattern of a gene may affect different steps in the
life of a cell (e.g. cell growth, adhesion, migration, inva-
sion and cell death) eventually leading to subsequent
tumor formation [5]. Several evidences of the association
between alternative splicing and cancer have been
reported. For example, it has been shown that about
half of all active alternative splicing events in ovarian
and breast tissues are altered in tumors, resulting in a
massive tissue type-specific reprogramming of alterna-
tive splicing [6]. These alterations seems to be linked to
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the RNA binding protein FOX2 whose expression is
downregulated in ovarian cancer and whose splicing
results extensively changed in breast cancer samples.
More recently, it has been reported that the presence of
an alternatively spliced isoform of the receptor for factor
VII/VIIa, named Tissue Factor (TF), is a prognostic
marker in patients with non-small cell lung cancer [7].
Indeed, this soluble isoform of TF lacking exon 5 that
encodes the transmembrane domain has been detected
in various cancerous tissues and several studies sug-
gested that its expression promotes tumor growth and is
associated with increased tumor cell proliferation and
angiogenesis in vivo [8]. Association of splicing with dis-
eases does not necessarily imply that alternative splicing
is a direct cause of cancer: aberrant splicing may be
consequence of indirect effects produced by the disease-
induced stress or may be caused by the general
misregulation of cellular functions [9]. Nonetheless, the
identification of a robust association between diseases
and specific splicing patterns could be very useful to
define signatures that can be used as diagnostic or prog-
nostic indicators, allowing to obtain medically relevant
information such as tumor stage and profiles [10,11].
The availability of an increasing number of genome
and transcript sequences, including Expressed Sequence
Tag sequences (ESTs) and more recently RNA-Seq data,
provides an essential information source for the compu-
tational detection of the alternative splicing pattern of
genes [1,2,12-15].
Currently, dbEST comprises more than 62 million
ESTs from several hundred organisms, the highest num-
bers for individual organisms being over eight million for
human [16]. Several bioinformatic tools have been devel-
oped for genome-wide detection of alternative splicing
based on pairwise alignments of cDNA and genomic
sequences [17,18]. To improve the prediction accuracy,
we developed a new tool, we named ASPic. ASPic imple-
ments an optimization strategy that performing a multi-
ple alignment of all available transcript data (including
full-length cDNA and EST sequences) to the genomic
sequence detects the intron set that minimizes the num-
ber of splicing sites. It also generates, through a DAG-
based combinatorial procedure, the minimal set of non-
mergeable transcript isoforms compatible with the
detected splicing events [19]. The reliability of splicing
isoforms detected by ASPic has been recently established
through a comparative assessment [20].
EST sequences have linked information about their
source sample (commonly including tissue, cancer, gen-
der, and developmental stage as well as organism infor-
mation) [21]. In particular, 45% of EST data are
collected from cancer tissues thus providing an invalu-
able source of information to study association of alter-
native splicing with cancer. Furthermore, the longer
read length of EST data with respect to those obtainable
from current next generation sequencing platforms may
provide relevant information on exon connectivity, thus
allowing a more accurate reconstruction of full length
alternative transcripts. Assuming that the expression
level of a splice variant in a certain source sample is
roughly proportional to the number of related ESTs in
the cDNA library [16], we may provide a qualitative and
quantitative association of the detected splice sites
according to tissue-specificity and tumor status.
Recently, several studies reported the identification of
cancer specific variants by combining the computational
analysis of the EST data with experimental validations
[22-24].
The availability of the unprecedented repertoire of
319,092 alternative splicing isoforms from 18,174 genes
collected in ASPicDB [2] predicted by a comprehensive
analysis of EST data included in the Unigene database
[25] prompted us to develop a reliable strategy for the
identification of cancer-associated isoforms. In particu-
lar, we focused our attention on the identification of
alternative normal- and tumor-specific cassette exons
which are particularly suitable as diagnostic or prognos-
tic cancer biomarkers or as therapeutic targets. Remark-
ably, we newly discovered several cassette exons with a
significant differential expression in normal and cancer
conditions. For some of them, we carried out an experi-
mental validation by RT-qPCR assays on commercial
RNA from the same anatomical system where they were
predicted. Considerably, we assessed the biomarker suit-
ability of some cassette exons, found differentially
expressed in the nervous system, in glioblastoma
patients. Our results provide support to our computa-
tional analysis and suggest that the relative ratio
between normal and tumor alternative transcripts may
represent a promising tumor biomarker.
Methods
Data source and computational analysis
We used as data source for the detection of cancer spe-
cific isoforms the ASPicDB database [2]. For all human
genes, ASPicDB provides information on all putative
splicing variants, as well as on the supporting ESTs of
each specific splice site. ESTs have been classified in 17
anatomical systems (see Figure 1) matching their library
information and following the nomenclature of the
“Cancer Genome Anatomy Project” http://www.ncbi.
nlm.nih.gov/ncicgap/[26]. We considered only those
anatomical systems for which at least 30,000 ESTs were
available in both the normal and tumor conditions.
To evaluate if the ESTs count between tumoral and
normal tissues was significantly different, we computed
upper-tail p-values (< 0.05) based upon the hypergeo-
metric distribution [16,27], also adopting the Bonferroni
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correction to address the problem of multiple compari-
sons. Given the large size of libraries and the small size
of the sample (count of ESTs) we did not assume a nor-
mal distribution (like in the Z-test used by Wang et al.
[24]) but we chose a nonparametric method. We classi-
fied in the same way splicing sites.
The analysis of Gene Ontology (GO) annotation was
performed using terms related to biological processes
[28]. Beside the Gene Ontology annotation available for
each human gene, we also assigned every parent term
up to the root discarding GO terms represented on gen-
ome scale by less than 50 genes.
Ontology terms assigned to genes classified as over-
represented in tumor condition (T/TT classes) or in phy-
siological condition (N/NN or E classes) were then identi-
fied and compared to their occurrence in the whole
genome set. Enriched GO classes were identified by using
Fisher’s exact test with a P≤0.01 cut off. The Ingenuity
Pathway analysis tool [29] has been used to detect specific
functional feature enrichments in selected gene sets.
RT-qPCR experiments
Total RNA from human normal (skeletal muscle and
brain) and tumor tissues (rhabdomyosarcoma and neu-
roblastoma) was purchased from commercial sources
(Ambion and Asterand, respectively). Glioma samples
were obtained from the Neurosurgery Department,
IRCCS Casa Sollievo della Sofferenza (San Giovanni
Rotondo, Italy). Informed consent was obtained for all
patients before the surgery as approved by the ethics
board. All tumors were histologically classified as glio-
blastoma multiforme (GBM, WHO grade IV). Samples
were collected immediately after surgical resection and
total RNA was extracted after having established pri-
mary glioma cell lines, with RNeasy Mini Kit (Qiagen)
accordingly to the manufacturer’s instructions.
cDNA synthesis was performed from 1 μg of total
RNA using QuantiTect® Reverse Transcription kit
(Qiagen).
Primers were designed with Primer3 software to detect
all splicing events determining the inclusion/exclusion of
the predicted tumoral or normal cassette exons. For
STRADA, PCNP and NAP1L1 genes, for which compu-
tational analysis identified two associated cassette exons,
primers were designed to amplify both exons or to
detect their simultaneous absence. For SLC25A3 gene,
where mutually exclusive exons were predicted, primers
were designed on specific exon junctions resulting from
alternative splicing events occurred. The sequences of
all primers are listed in Additional File 1.
1 μl of each cDNA (dilution 1:10) was used as tem-
plate in qPCR assays, performed in triplicate on ABI
PRISM 7900HT (Applied Biosystems) using the Quanti-
Tect® SYBR Green PCR Master Mix (Qiagen). Amplifi-
cation parameters were as follows: hot start at 95°C for
15 min; 50 cycles of amplification (94°C for 15 sec, 62°C
for 30 sec, 72°C for 30 sec); dissociation curve step (95°
C for 15 sec, 60°C for 15 sec, 95°C for 15 sec). Fluores-
cence raw data were exported from the SDS 2.2.1 soft-
ware (Applied Biosystems) and analyzed with
the DART-PCR Excel workbook [30]. For each tissue,
the relative expression ratio (rER) of transcripts with
the assayed cassette exons respect to those lacking
them was calculated applying the following formula:
(1 + E(w/o exon))
Ct(w/o exon)/(1 + E(with exon))
Ct(with exon),
where E is the average amplification efficiency calculated
Figure 1 Genes and introns classification based on ESTs data
analyses. (A) Number of available ESTs for each tissue, classified as
normal (N) or tumoral (T), according to the CGAP classification. (B)
Number of genes analyzed for each tissue, classified on the base of
their expression in the normal (N and NN) and tumoral (T and TT)
status and of comparable expression in both conditions (E). (C)
Number of tumoral (T) and normal (N) specific introns for each
tissue. BMA: Bone marrow, BRE: Breast, CNS: Central nervous system
(e.g. brain); COL: Colon; DER: Skin; END: Endocrine system; EYE: Eye;
INT: Gastrointestinal tract; KID: Kidney; LIV: Liver; LYM:
Lymphoreticular system; MSK: Musculoskeletal system; PLA: Placenta;
PRO: Prostate; RES: Respiratory System; STO: Stomach; TES: Testis
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by DART-PCR for each primers pair and Ct is the aver-
age Ct obtained for the presence of the cassette exon or
for its absence. No normalization was needed because
comparisons were carried out between targets in the
same sample. The data shown are the average from at
least three independent experiments.
Results
Genes and introns classification and prediction of
alternative splicing transcript variants
To carry out our genome-wide analysis of cancer
related splicing isoforms, we considered all data col-
lected in our ASPicDB database [2] including over
18,000 genes and 300,000 alternative transcripts.
As depicted in Figure 1A, the number of available
ESTs was quite heterogeneous for the different tissues.
More than 900,000 ESTs derive from central nervous
system (CNS) and - on average - about 210,000 ESTs
are available for all the other considered tissues. The
ratio between tumoral and normal ESTs is close to one
in tissues like gastrointestinal tract (INT), kidney (KID)
and testis (TES), as the number of available ESTs in the
two conditions is almost the same. Tissues like colon
(COL) and prostate (PRO) are enriched by sequences
obtained from tumoral libraries, conversely placenta
(PLA) and central nervous system (CNS) contain more
ESTs obtained from normal tissues.
The overall expression of each gene (represented by at
least 10 ESTs) has been evaluated in all the considered
anatomical groups and in both the normal and neoplas-
tic status. For each gene - and for each tissue - we com-
pared the number of ESTs from normal and neoplastic
samples. Genes were grouped into five categories: genes
exclusively expressed in normal condition (NN); genes
exclusively expressed in neoplastic condition (TT);
genes over-expressed in normal condition (N); genes
over-expressed in neoplastic condition (T); genes with
comparable expression in both normal and neoplastic
conditions (E). Figure 1B summarizes, for each tissue,
the distribution of genes in the five different classes. As
expected, the number of classifiable genes in each tissue
- although relatively small compared to the total num-
ber of analyzed genes - reflects the abundance of avail-
able ESTs. As a matter of fact, the highest number of
classified genes (> 7000) belongs to CNS. On average,
40% of genes do not show a statistically significant dif-
ferential expression in the two conditions (class E). The
remaining 60% of genes are distributed among the 4 dif-
ferent classes (TT, T, NN, N). Bone marrow (BMA),
breast (BRE), skin (DER), liver (LIV) and placenta (PLA)
show a significant bias toward genes over-expressed in
tumors (T and TT). Conversely, central nervous system
(CNS) and prostate (PRO) are enriched in genes mainly
expressed in normal tissues (N and NN). The genes
exclusively expressed in the neoplastic condition in the
different tissues, which could be considered tumoral
markers in a specific tissue, are listed in Additional File
2.
In order to assess if genes mainly expressed in tumor
cells with respect to genes resulting mainly or equally
expressed in normal tissues were enriched in specific
functional categories, we performed a statistic analysis
using the Gene Ontology annotation. The occurrence of
each GO term in cancer associated genes (T and TT
classes) and in genes classified as N, NN or E was com-
pared to its occurrence in the whole genes set thus
identifying significantly over-represented ontologies by
applying Fisher’s exact test. Additional File 3 lists the
top 10 most frequent terms in the two genes sets. Our
results, not surprisingly, show that genes mainly
expressed in normal tissues are related to general meta-
bolic processes, while genes associated to cancer show -
as expected - a sizable enrichment of processes related
to cell proliferation, apoptosis and cell cycle.
In order to identify cancer or normal specific introns,
we considered in our analysis all transcript-supported
splices of genes belonging to the T, N and E classes,
excluding genes belonging to the TT and NN classes.
As shown in Figure 1C and detailed in Additional File 4,
the majority of classified splicing events belongs to CNS
with 18,436 classified introns, due to the higher number
of ESTs available for CNS (Figure 1A). With few excep-
tions (e.g. colon, prostate and stomach), a general preva-
lence of tumor associated introns can be observed, with
eye and placenta showing a noticeably 96% and 92% of
tumor associated introns. This pattern is not related to
the differential abundance of normal and tumor specific
ESTs, as shown in Figure 1A. Indeed, for colon, pros-
tate, and stomach, tumor associated-ESTs largely out-
number normal ones (Figure 1A).
By using the methodology described in Methods, we
classified 26,974 splice sites as tumor- (T or TT) and
21,120 as normal- (N or NN) specific from 9513 genes.
Given the variable number of aligned ESTs for each
gene and their uneven coverage across its length, each
splice site was classified in one or more tissues. For
example, only three splices were classifiable in all 17 tis-
sues considered and 991 in at least 10 tissues. We then
investigated the classification concordance for introns
labeled in five or more tissues. In most of cases (2993
introns, 62.2%) we detected an heterogeneous classifica-
tion where the same intron was classified normal in
some tissues and tumoral in others. For example, the
first intron of PPP2R1A gene was exclusively expressed
in the normal END tissue and in the tumoral BMA tis-
sue (see Additional File 5). The remaining cases were
homogeneously tumoral (1610, 33.5%) or normal (205,
4.3%).
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We finally evaluated the classified introns on the basis
of the spliceosomal machinery by which they are recog-
nized (U2 or U12 spliceosome) without detecting any
significant bias (data not shown).
Identification of alternative Tumoral/Normal
introns and cassette-exons and mutually exclusive
exons
The further step of our analysis was aimed to the
identification of alternative N- and T-specific introns,
based on their overlapping coordinates. Table 1 sum-
marizes - for each considered tissue - the number of
genes for which we were able to identify at least one
tumor-associated splicing event not compatible (i.e.
alternative) with a normal-associated one. The number
of alternative tumoral and normal introns is also
reported. We identified the highest number of genes
[22] in the CNS, fitting the above mentioned criterion,
related to the high number of available ESTs for this
tissue.
To detect cancer (or normal) specific cassette exons,
we selected those genes characterized by the simulta-
neous occurrence of at least one cancer specific splice
site and at least one normal specific splice site defining
overlapping introns (Table 1). The presence of a
tumoral (or normal) cassette exon or mutually exclusive
exons was defined by two cancer specific splice site
pairs, alternative to one or two normal specific splice
site pairs (or viceversa) (Figure 2).
We identified a total of 46 genes (for two of them,
HLA-B and HLA-C, predictions were related to more
than one anatomical group) with 88 condition-specific
cassette or mutually exclusive exons, specifically 34
tumor-specific exons and 54 normal-specific exons
which are spliced out in the tumoral isoforms. Interest-
ingly, only one gene (SLC25A3) revealed mutually exclu-
sive exons. For any of these cassette exons a differential
expression in the normal and cancer conditions was pre-
viously reported.
We have investigated specific functional feature enrich-
ments in these 46 genes by using DAVID [31] and Inge-
nuity Pathway Analysis [29]. Results are reported in
Additional Files 6 and 7. Interestingly, the two top net-
works associated to this gene set concern cell function
and maintenance and cell cycle. Also, an over-representa-
tion of cancer associated genes (23/46) can be detected.
Concerning structural properties of the protein
sequences encoded by cassette exons, a remarkable
domain enrichment can be observed as 36/46 cassette
exons overlapped annotated domains (78.3%) in contrast
to the 54.4% (111,456/204,934) generally observed for
protein coding internal exons in human genes.
Table 2 lists all genes for which we identified tumoral-
or normal-specific cassette exons, including mutually
exclusive exons (see Additional File 8 for a full list of
the cassette exons).
Experimental validation of specific cassette exons by
RT-qPCR
To experimentally validate our in silico predictions of the
condition-specific cassette exons, we selected 7 normal-
predicted cassette exons (detected in ATP6v0A1,
STRADA, PCNP, TPM3 and TPD52L2 genes), 4 tumoral-
predicted cassette exons (detected in CS, METT10 D and
NAP1L1 genes) and 1 pair of mutually exclusive-predicted
exons (detected in SLC25A3 gene) (Table 3).
We performed RT-qPCR assays, using total RNA
derived from the same type of biological source (normal
and tumoral) in which they were predicted. Notably, we
compared the presence of the specific cassette exons in
RNA from normal brain and neuroblastoma (for
Table 1 Number of genes with normal and tumoral












CNS 22 92 59 33 9 34
DER 4 16 5 11 8 1
EYE 2 7 3 4 2 1
KID 1 3 1 2 1 0
LIV 1 3 2 1 0 1
LYM 4 17 9 8 4 4
MSK 7 24 13 11 3 6
PLA 2 6 3 3 1 1
RES 2 12 5 7 4 2
TES 5 17 10 8 2 4
Total 50 197 109 88 34 54
Figure 2 Cassette and mutually exclusive exons. Schematic
representation of a tumoral cassette exon (A) and mutually
exclusive exons (B). Tumoral cassette exon or mutually exclusive
exons are defined by two cancer specific splice site pairs, alternative
to one or two normal specific splice site pairs.
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ATP6v0A1, STRADA, PCNP and CS) and from skeletal
muscle and rhabdomyosarcoma (for TPM3, TPD52L2,
NAP1L1, METT10 D and SLC25A3). Primers were
designed to specifically amplify transcripts without or
with cassette exons (w/o CE and with CE) (Figure 3).
For each gene, we evaluated the relative expression ratio
(rER) between transcripts containing cassette exons and
transcripts without cassette exons in both normal and
tumoral conditions of the anatomical group. We found
that all computational predictions, but one, were
Table 2 Genes containing normal (N) or tumor (T)-specific cassette exons predicted in silico
Gene Tissue(s) Cassette Exon(s) Description
ACTN1 CNS N actinin, alpha 1
ALDOA TES N aldolase A, fructose-bisphosphate
ATP6V0A1 CNS N ATPase, H+ transporting, lysosomal V0 subunit a1
CS CNS T citrate synthase
CTNNA1 CNS N catenin (cadherin-associated protein), alpha 1, 102kDa
DCTN1 CNS N/T dynactin 1 (p150, glued homolog, Drosophila)
EEF1D EYE T eukaryotic translation elongation factor 1 delta (guanine nucleotide exchange protein)
EWSR1 CNS N Ewing sarcoma breakpoint region 1
FAM104A TES N family with sequence similarity 104, member A
FAM49B CNS N family with sequence similarity 49, member B
GSN KID T gelsolin (amyloidosis, Finnish type)
HDLBP CNS T high density lipoprotein binding protein
HLA-B RES, LYM, MSK N/T major histocompatibility complex, class I, B
HLA-C LYM, MSK, DER N/T major histocompatibility complex, class I, C
HLA-DRB1 CNS T major histocompatibility complex, class II, DR beta 1
HSPA8 DER T heat shock 70 kDa protein 8
IARS CNS N isoleucyl-tRNA synthetase
IDH3A LYM N isocitrate dehydrogenase 3 (NAD+) alpha
ITIH4 LIV N inter-alpha (globulin) inhibitor H4
LDHA DER N lactate dehydrogenase A
LMNA DER T lamin A/C
METT10D CNS T methyltransferase 10 domain containing protein
MYL6 PLA N myosin, light chain 6, alkali, smooth muscle and non-muscle
MVK CNS N mevalonate kinase
NAP1L1 MSK T nucleosome assembly protein 1-like 1
NDRG4 CNS N N-myc downstream regulated gene family member 4
NRSN2 CNS N neurensin 2
PCNP CNS N PEST proteolytic signal containing nuclear protein
PKM2 TES N pyruvate kinase, muscle
PLEKHB1 EYE N pleckstrin homology domain containing, family B member 1
POMT1 TES T protein-O-mannosyltransferase 1
PRKCZ PLA T protein kinase C, zeta
RAN RES T RAN, member RAS oncogene family
RPH3A CNS N rabphilin 3A homolog (mouse)
RPS24 MSK N ribosomal protein S24
SELENBP1 CNS N selenium binding protein 1
SLC25A3 MSK N/T solute carrier family 25 (mitochondrial phosphate carrier), member 3
STRADA CNS N STE20-related kinase adaptor alpha
TMEM87A CNS N transmembrane protein 87A
TPD52L2 MSK N tumor protein D52-like 2
TPM3 MSK N tropomyosin 3
UQCC CNS N ubiquinol-cytochrome c reductase complex chaperone
WARS LYM T tryptophanyl-tRNA synthetase
YPEL5 CNS T yippee-like 5 (Drosophila)
ZFAND6 TES N zinc finger, AN1-type domain 6
ZNF655 CNS T zinc finger protein 655
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validated in the in vivo analysis. For ATP6v0A1,
STRADA, PCNP, TPM3 and TPD52L2 genes, the rela-
tive quantification analysis confirmed the presence of
the normal-predicted specific cassette exons (Figure 3A).
For ATP6v0A1 gene, we observed that the normal
predicted exon A, which is known to be included in the
three transcript variants of this gene, is present in both
normal and tumoral conditions, although it was preva-
lent in the normal brain sample.
For STRADA gene, multiple transcripts were
described, some of them missing exon F and/or G,
which encode for a portion of a kinase domain. We
observed that, in normal brain, transcripts containing
both F and G cassette exons are ~2-fold more abundant
than the others and they are ~3-fold less expressed
respect to transcripts lacking them in neuroblastoma.
Therefore, F and G cassette exons showed a normal
condition association, as predicted.
For PCNP gene, our computational analysis predicted
two adjacent cassette exons, D and E, as normal-specific.
We found that transcripts containing both these exons
are more abundant than those lacking them in both
normal and tumoral conditions, although they are ~3-
fold less expressed in neuroblastoma respect to normal
brain. Therefore, we classified exons D and E as normal
cassette exons.
For TPM3 gene, multiple transcripts were reported,
but only isoform 1 (NM_152263.2) contains cassette
exon M. We found that this transcript is expressed at
very low level respect to transcripts lacking exon M in
the tumoral condition (more than 20,000 fold less), vali-
dating exon M as normal specific cassette exon.
For TPD52L2 gene, multiple transcripts were
described, some of which lack exon L that we analyzed.
We confirmed that exon L is normal-associated, as
predicted. Indeed, we found that exon L containing
transcripts are more expressed in both conditions
respect to those lacking it, but they show a reduction
(~2-fold) of their expression in rhabdomyosarcoma.
Figure 3B shows results for tumoral-specific cassette
exons validation for CS and NAP1L1 genes.
For CS gene, our computational analysis predicted
exon B as tumor-specific. We found that transcripts
containing this exon are very low expressed, both in
absolute terms and respect to transcripts missing it.
Nevertheless, we observed that in neuroblastoma there
is a ~3-fold increase of exon B presence respect to nor-
mal brain, allowing us to validate exon B as tumor-
associated.
For NAP1L1 gene, two adjacent cassette exons, H and
I, were predicted as tumoral specific. We observed that
NAP1L1 transcripts including these cassette exons are
expressed in both normal and tumoral conditions, but
they are much more expressed in rhabdomyosarcoma
respect to normal skeletal muscle tissue (about 5-fold).
Figure 3C shows the analysis of a pair of mutually
exclusive cassette exons, K and J, for SLC25A3 gene.
We confirmed the in silico predictions, as normal-
predicted exon K (considered as calibrator) is
more abundant than exon J (~10-fold) in normal skele-
tal muscle tissue and less expressed (~250-fold) in
rhabdomyosarcoma.
The RT-qPCR assays did not validate the tumor-speci-
fic cassette exon predicted for METT10D in MSK, as it
resulted as normal-specific (data not shown). This could
be probably due to the heterogeneity of the ESTs source
used for the computational analysis, likely different from
the one used for the experimental assay.
The validation of the cassette exons specific for the
nervous system, detected for ATP6v0A1, STRADA,
Table 3 Predicted normal (N) and tumoral (T) cassette exons analyzed by RT-qPCR
Anatomical group Gene1 Exon(s) labels Exon(s) absolute coordinates Exon(s) length (bp) Predicted expression specificity
CNS ATP6V0A1 [38] A Chr17:37919833-37920004 172 N
CNS CS [39] B Chr12:54971682-54971844 163 T
CNS METT10 D [40] C Chr17:2325285-2325343 59 TT
CNS PCNP [41] D Chr3:102786971-102787045 75 + 56 NN
E Chr3:102791749-102791804
CNS STRADA [42] F Chr17:59157730-59157787 58 + 29 N
G Chr17:59154390-59154418
MSK NAP1L1 [43] H Chr12:74748956-74749041 86 + 103 TT
I Chr12:74747418-74747520
MSK SLC25A3 [44] J Chr12:97513636-97513757 122 TT
MSK SLC25A3 K Chr12:97513342-97513466 125 N
MSK TPD52L2 [45] L Chr20:61977613-61977672 60 NN
MSK TPM3 [46] M Chr1:152408405-152408483 79 NN
1 In the brackets are gene specific bibliographic references.
The anatomical group, the gene name, the exon label, genomic coordinates (NCBI36/hg18), exon length and predicted expression specificity are reported.
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PCNP and CS genes, prompted us to analyze their
expression in patients affected by glioblastoma, the most
frequent form of primary intracranial malignancy.
Results are reported in Figure 4. We found that, respect
to normal samples, STRADA and PCNP transcripts con-
taining the predicted normal specific exons are less
expressed in all tumoral samples respect to those lack-
ing them. In particular, for STRADA gene we observed
a switch between the two classes of transcripts, with a
strong reduction of transcripts with the two CEs encod-
ing the kinase domain of STRADA protein. For
ATP6v0A1 gene, transcripts containing the predicted
normal cassette exon are more expressed respect to
those lacking it in tumoral samples, although their
expression is reduced respect to the normal samples.
Finally, for CS gene, although transcripts containing the
tumoral predicted cassette exon are less expressed
respect to those lacking it in all normal and tumoral
samples, we found that these transcripts are more
expressed in tumoral samples respect to normal brain
samples.
Figure 3 Expression analyses of some normal/tumoral predicted cassette exons. Experimental validation of normal (A), and tumoral (B)
predicted cassette exons (CE) and a pair of mutually exclusive CEs (C) by RT-qPCR. w/o CE = transcripts lacking CE; with CE = transcripts
containing CE. For each condition, results are expressed as relative expression ratio of transcripts containing CE respect to transcripts lacking CE,
used as calibrator. For each gene, a schematic representation of alternative transcripts and primer pairs used are reported.
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Discussion
Alternative splicing is widely recognized as a post-tran-
scriptional regulatory mechanism which plays an impor-
tant role in modulating gene expression in different
tissues and developmental stages. Moreover, some alter-
natively spliced isoforms are associated with different
diseases including cancer [5,23,24,32]. Actually, muta-
tions at the exon-intron junctions or affecting exonic or
intronic splicing regulatory elements can contribute to
the development of neoplastic states.
Histological information deriving from EST libraries
annotation can be very useful in defining the expression
profile of tumoral cells. The presence of a high number
of tumoral ESTs and the absence of normal ESTs (or
viceversa) mapping on a precise genomic region could
mean that, in a cell, the presence/absence of a gene pro-
duct may be cause or consequence of the tumoral
pathology. The observation that the same gene may
express many structurally and functionally different pro-
ducts, not only changed radically the traditional gene
definition [33] but also extended the perspective of the
analysis of differential expression in the normal and
tumoral conditions beyond the gene level, taking into
account alternative transcripts and proteins.
In this work, we have focused our attention on the
study of alternative splicing aimed to the identification
of cancer specific isoforms. Our method involves the
characterization of splice sites with information deriving
from EST libraries despite some intrinsic limitations of
such data (34). Several studies of differential expression
between the normal and tumoral conditions have been
previously reported [23,24,35] through in silico analyses.
Some predictions were also experimentally validated and
collected in specialized databases, like ASAPII [13]. The
method we developed for the classification of normal
and tumoral introns differs from that used in ASAPII
for two main reasons: 1) the statistics used; 2) the logic
adopted for the definition of cancer specificity. Indeed, a
serious limitation of the ASAPII database is that cancer
specificity is detached from the tissue information as
introns are classified cancer-specific regardless of the
source tissue. In this way, as the Authors also report,
some information can be lost or hidden by the general
expression pattern of the gene, which may be tissue-spe-
cific. For example, in our analyses, for the KRT7 gene,
the same splice site can be classified as normal- or can-
cer-specific depending on the tissue type considered
(see Additional File 9). Such type of introns remain
unclassified in the ASAPII database because it merges
together ESTs from different tissues thus causing the
flattening of the signal.
Another difference is represented by the fact that we
define the splice site specificity in an absolute manner
while in ASAPII database the tissue or histological spe-
cificity of each splice site is defined in comparison to
another splice site. For the Tryptophanyl-tRNA synthe-
tase gene (WARS), for example, the same splice site has
been classified tumoral or normal depending on the
other splice site with which it was compared to. In this
way each splice site can not be univocally classified.
We approached the study of alternative splicing and
its association to cancer, focusing, in the first part of the
work, on the gene differential expression in normal and
tumoral conditions among different tissues, in order to
exclude from our candidate cancer specific splicing
events, splice sites belonging to genes expressed in only
one histological condition. We performed the classifica-
tion analysis at intron level. The observation that CNS
is the tissue with the highest number of tumor-specific
splicing could imply some biological meaning or it
could simply reflect the larger number of available nor-
mal and tumoral ESTs for the statistical validation.
Figure 4 Expression analyses of some CNS predicted cassette exons in gliobastoma samples. Experimental validation of nervous system
specific predicted cassette exons (CEs) of STRADA, PCNP, ATP6v0A1 and CS genes by RT-qPCR in normal brains and in 8 patients affected by
glioblastoma. Statistical analysis was performed using an unpaired one-tail T-test. w/o CE = transcripts lacking CE; with CE = transcripts
containing CE. For each condition, results are expressed as relative expression ratio of transcripts containing CE respect to transcripts lacking CE,
used as calibrator.
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Moreover, we specifically focused our attention on
cassette exons to increase the reliability of statistical
assessments, because of the necessity of a simultaneous
occurrence of statistically validated tumor and normal-
specific splicing sites, and to provide a collection of
tumor biomarkers easily assayable and potentially suita-
ble to be tested as therapeutic targets (e.g. using specific
antibodies carrying cytotoxic agents).
Given the genome-wide approach (more than 18,000
genes analyzed), the number of significant results, a
total of 88 cases, may not seem very high, but it must
be recalled that we have used very stringent criteria
which require simultaneous EST support for at least
three splicing sites in both the normal and the tumoral
status (see the data-flux flowchart in the Additional File
10). Furthermore, it should be considered that differen-
tial expression was based on EST counts from pooling
normal and tumor libraries, thus loosing the replicate
information. Forthcoming efforts using the huge amount
of data provided by next-generation sequencing could
suitably address this issue.
Our methodology has not identified all genes known
to be characterized by the presence of tumor specific
isoforms. For some genes like MDM2 and MDM4 [5],
this was due to the insufficient number of available
ESTs, either tumoral or normal, to define intron histolo-
gical specificity. For CD44 [23] or TP53 [36] genes, we
found cancer-specific splice sites in many tissues, but
the number of normal ESTs was not sufficient to find
significant normal-specific introns. Beside the small
number of ESTs supporting introns prediction, another
problem encountered has been the lack of ESTs annota-
tion. The absence of information concerning tissue or
histology associated to libraries led us to the exclusion
of many EST sequences from the classification analysis.
It is thus essential to reaffirm the importance of a good
sequence annotation.
Finally, in order to provide a more accurate and quan-
titative estimate of the expression specificity of the pre-
dicted cassette exons, we carried out RT-qPCR assays.
We found that all predicted normal or tumoral specific
transcripts, but one, were confirmed in vivo in the same
type of biological source (normal and tumoral) in which
they were predicted. Of particular interest was the speci-
fic expression of ATP6v0A1, STRADA, PCNP and CS
transcript variants, analyzed in patients affected by glio-
blastoma, which confirmed all the predicted cassette
exons, thus demonstrating the reliability of our compu-
tational analysis. In particular, the cassette exons we
identified in the STRADA gene represent a very promis-
ing biomarker as their significant differential expression
in the normal and cancer conditions is homogeneously
conserved in all samples analyzed.
Conclusion
We present a novel computational strategy for in silico
identification of tumor-associated transcript variants to
be used as cancer molecular biomarkers, that was sup-
ported by the experimental validation which demon-
strated that cassette exons are differently associated to
normal/tumoral condition. In particular, we assessed the
biomarker suitability of some cassette exons, found dif-
ferentially expressed in the nervous system, in patients
affected by glioblastoma.
This methodology can be easily adapted to manage
exon array hybridization data [4] and next-generation
sequencing data [37], thus opening unprecedented
opportunities for a thorough investigation of the expres-
sion pattern in human and other organisms.
Additional material
Additional file 1: Primers used in RT-qPCR validations. This table
reports the sequences of all primers used in the validation experiments
and the relative amplicon sizes.
Additional file 2: List of 1375 genes exclusively expressed in the
tumor status and tissue. For each gene this table reports the tissue
type (see the legend of Fig. 1), the number of ESTs from tumor libraries
and their total size, the p-value calculated as described in the Method
section. A total of 469 genes result statistically significant also after the
Bonferroni correction (*) at 0.05 confidence level.
Additional file 3: Top 10 represented GO terms among genes over-
represented in tumor (T/TT) and normal (N/NN) tissues. For each GO
term this table reports the GO identifier (GO_Id), the number of genes,
the P value (P-val) and the description (GO_Description). Only Gene
Ontology terms assigned to more than 50 human genes were
considered.
Additional file 4: Genes and splicing sites showing a normal or
tumor specific expression. For each tissue this table reports the
number of genes and splicing sites with a labeled expression pattern as
described in the text (total numbers after the Bonferroni correction at
the 0.05 confidence level are in the brackets)
Additional file 5: Heterogeneous classification of the first intron of
the PPP2R1A gene (intron #4 following ASPidDB nomenclature
located at chr19:57385240-57397008). Expression pattern of intron #4
of the PPP2R1A gene where is shown the number of supporting ESTs
from normal and cancer tissues, the statistical significance and the
classification. This intron is exclusively expressed in tumor bone marrow
(BMA) and in normal endocrine system (END) (see red arrows).
Additional file 6: Functional analysis of 46 genes characterized by a
normal- or tumoral- specific cassette exon. The file contains enriched
biological terms identified with DAVID (Database for Annotation,
Visualization and Integrated Discovery) v6.7 (page 1). Most significant
terms include “acetylation”, “phosphoprotein” and “alternative splicing”.
An Ingenuity Pathway Analysis, which delivers an assessment of the
signalling and metabolic pathways, molecular networks, and biological
processes that are most significantly perturbed in a dataset of interest, is
also included (pages 2-8). The “Top Networks” section contains the four
networks, with a statistically significant score, that could be detected
from the input dataset. The network with the highest score (score = 42)
is significantly enriched in the following functions: Cell-mediated Immune
Response, Cellular Function and Maintenance, Hematological System
Development and Function. The report also includes (pages 7 and 8) a
graphical representation of two top networks which comprise genes
belonging to the network and the relationships among them. Other key
components of the IPA Core Analysis, shown in the report, are: “Diseases
and Disorders”, “Molecular and Cellular Functions” and “Physiological
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System Development and Function”. The number of molecules (i.e.
genes) belonging to the different classes and associated p-values are
reported.
Additional file 7: IPA analysis data. A gene list for each of the four top
functional networks is reported in the “Top_network” sheet. The
“CE_proteindomains” sheet lists the protein domains encoded by the
condition-specific (normal or tumoral) cassette exons.
Additionale file 8: List of predicted normal (A) and tumor (B)
-specific cassette exons. The anatomical group, the gene name, the
genomic coordinates (NCBI36/hg18), and the unique transcript ID
following Riva and Pesole (2009) are reported.
Additional file 9: Expression pattern of intron #12 of KRT7 gene.
ASPicDB table relative to the expression pattern of intron #12 of the
KRT7 gene (following ASPicDB nomenclature, located at chr12:50917621-
50918730) showing the number of supporting ESTs from normal and
cancer tissues, the statistical significance and the classification.
Additional file 10: Data flux flowchart. The flowchart reports the
number of genes at each step in the detection of normal or cancer-
specific cassette exons.
Abbreviations
AS: alternative splicing; ESTs: Expressed Sequence Tag sequences; RT-qPCR:
Reverse Transcriptase-quantitative Polymerase Chain Reaction.
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